---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343473"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-08-11T12:03:41+00:00"
generated_at: "2026-08-11T12:05:05.907808+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coya Q2 2026 net loss $6.6M; cash $43.2M funds ALS trial into 2H27

## Summary
- Net loss $6.6M for Q2 2026 vs $6.1M in Q2 2025; R&D up $1.3M to $5.0M on COYA 302 ALS trial costs.
- Cash and equivalents $43.2M at June 30, 2026, expected to fund operations past Phase 2 ALSTARS readout into 2H 2027.
- FDA granted Fast Track Designation for COYA 302 in ALS; first cohort advanced into 24-week blinded active treatment extension.
- Collaboration revenue flat at $0.2M under DRL agreement; G&A down $0.6M to $2.3M.
- On track to complete ALSTARS enrollment in 2H 2026 and report topline data in Q1 2027; Phase 2 FTD study to initiate in 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-343473
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-08-11T12:03:41+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/0001193125-26-343473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343473
- JSON: https://secwatch.observer/filing/0001193125-26-343473.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.